| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/21/2006 | CN1791408A Treatment of neurological conditions |
| 06/21/2006 | CN1791405A Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2a receptor |
| 06/21/2006 | CN1791397A Pharmaceutical combination comprising modafinil and another drug |
| 06/21/2006 | CN1789246A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 06/21/2006 | CN1788790A Extrasin beta-16 for promoting vascularization, tissue regeneration and wound healing |
| 06/21/2006 | CN1788786A Submicroemulsion composition for injection and preparation process thereof |
| 06/21/2006 | CN1788780A Medicine for abstaining from drug |
| 06/21/2006 | CN1788770A Numbness relieving and pain relieving ointment |
| 06/21/2006 | CN1788722A Composition for preventing or treating dementia |
| 06/21/2006 | CN1788721A Injectable buprenorphine microparticle compositions and their use |
| 06/21/2006 | CN1788720A Use of symipristone analog for treating depression |
| 06/21/2006 | CN1788609A Preparation method of gastrodia tuber essence serial health product |
| 06/21/2006 | CN1260227C 5-membered ring heterocyclic compounds with nitrogen |
| 06/21/2006 | CN1260226C Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mGluR1 antagonists |
| 06/21/2006 | CN1260225C Tetrahydropyridino or piperidino hetlrocyclic derivatives |
| 06/21/2006 | CN1259974C Drug giving-up medicine made-up by non-thebaica medicines |
| 06/21/2006 | CN1259969C Compound brain-tonifying and intellect-strengthening capsule and its preparation process |
| 06/21/2006 | CN1259911C Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 06/21/2006 | CN1259903C Slow release bioadhesive buccal tablet |
| 06/20/2006 | US7064236 such as dimethyl-[phenyl-(2-phenyl-cyclohex-1-enyl)-methyl]-amine for treatment of pain, depression, hypotension, senile dementia, tinnitus, hearing loss, epilepsy, obesity, cachexia, urinary incontinence, anxiolysis, diuresis, and alzheimer's disease |
| 06/20/2006 | US7064217 2-Aminoacetamide derivatives with hydroxy-, phosphonate-, and/or methylene phosphonate substituent; antitumor, anticoagulant, antiproliferative, and wound healing agents |
| 06/20/2006 | US7064215 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease |
| 06/20/2006 | US7064204 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders |
| 06/20/2006 | US7064189 Antibodies that immunospecifically bind to trail receptors |
| 06/20/2006 | US7064148 Such as 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E for treatment of cystic fibrosis; lubiprostone |
| 06/20/2006 | US7064147 Amino acids with affinity for the α-2-delta-protein |
| 06/20/2006 | US7064143 4-oxy- or amino-substituted indole-2-carboxy acids, esters and amides, e.g., ethyl 4-hydroxy-1-methyl-1H-indole-2-carboxylate and N-methyl-N-phenethyl 4-hydroxy-1-methyl-1H-indole-2-carboxamide; used for treatment of Alzheimer's disease, anxiety or schizophrenia |
| 06/20/2006 | US7064140 linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group; also containing an opioid analgesic; enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect. |
| 06/20/2006 | US7064138 Also treating bulimia nervosa, irritable bowel syndrome, urinary incontinence, asthma, bradycardia, and bradyarrhythmia |
| 06/20/2006 | US7064137 Analgesics; anxiolytic agents; gastrointestinal disorders |
| 06/20/2006 | US7064136 Central nervous system disorders; psychological disorders; schizophrenia; antiarthritic agents; Alzheimer's disease; anticancer agents |
| 06/20/2006 | US7064128 Preferentially substituted calcium channel blockers |
| 06/20/2006 | US7064123 substituted acetamides; uses for treating diseases including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, and metachromatic leukodystrophy |
| 06/20/2006 | US7064120 For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates |
| 06/20/2006 | US7064119 with a hexahydro-5-oxo-4-phenylpyrimido[4,5-b][1,5]diazocine or tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin e ring; treating dysuria, especially increased urinary frequency or incontinence |
| 06/20/2006 | US7064118 Cholinergic ligands of the nicotinic acetyl choline receptors; modulators; nervous system disordes, analgesics; smooth muscle contraction; antiinflammatory agents; drug abuse, including smoking; Alzheimer's disease; Parkinson's disease; cognition |
| 06/20/2006 | US7064116 GABAA modulating neurosteroids |
| 06/20/2006 | US7064115 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| 06/20/2006 | US7063964 Nucleic acids encoding IL-12 antibody |
| 06/20/2006 | US7063953 Human voltage gated sodium channel β1A subunit and methods of use |
| 06/20/2006 | US7063864 Morphine sulphate microgranules, method for preparing same and compositions containing same |
| 06/20/2006 | US7063835 Virus strains |
| 06/20/2006 | US7063832 Treating musculoskeletal pain or restless leg syndrome by breathing a muscle relaxant condensation aerosol having a mass median aerodynamic diameter (MMAD) of <3 mu m and <5% relaxant degradation products; kits; heating a coating of drug on a support to vaporize and passing air through the heated vapors |
| 06/20/2006 | US7063831 Delivery of erectile dysfunction drugs through an inhalation route |
| 06/20/2006 | US7063830 condensation aerosol for delivery of lidocaine, verapamil, diltiazem, isometheptene and lisuride, wherein aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form aerosol |
| 06/20/2006 | CA2379633C Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| 06/20/2006 | CA2379585C Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| 06/20/2006 | CA2176144C Anthracycline derivatives for treatment of amyloidosis |
| 06/20/2006 | CA2162706C 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease |
| 06/20/2006 | CA2121523C Sulfonamide derivatives |
| 06/15/2006 | WO2006063247A2 Regulated expression of transgenes in the central nervous system of mammals |
| 06/15/2006 | WO2006062481A1 New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| 06/15/2006 | WO2006062422A1 Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions |
| 06/15/2006 | WO2006062135A1 Diagnostic for mental disease |
| 06/15/2006 | WO2006062110A1 Piperazine derivative |
| 06/15/2006 | WO2006061711A1 1, 2, 3, 3a, 8, 8a-hexahydro-2, 7a-diada-cyclopenta [a] inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders |
| 06/15/2006 | WO2006061624A1 Compositions for use in surgery |
| 06/15/2006 | WO2006061428A2 Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| 06/15/2006 | WO2006061392A2 Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives |
| 06/15/2006 | WO2006061379A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061378A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061377A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061376A1 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061374A1 Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites |
| 06/15/2006 | WO2006061136A2 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer’s disease |
| 06/15/2006 | WO2006061135A1 Phenyl-piperazin methanone derivatives |
| 06/15/2006 | WO2006044573A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 06/15/2006 | WO2006044379A3 Novel curcumin analogues and uses thereof |
| 06/15/2006 | WO2006042479A9 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 06/15/2006 | WO2006021000A3 Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon |
| 06/15/2006 | WO2005113526A3 Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| 06/15/2006 | WO2001082928A9 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 06/15/2006 | US20060129385 Cholinergic therapy for individuals with learning disabilities |
| 06/15/2006 | US20060128993 Used to treat mood (depression), anxiety (obsessive compulsive disorder), behavioral, eating, substance abuse and sexual disorders and for prevention of migraines; (1S,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| 06/15/2006 | US20060128786 Compounds for the treatment of alzheimer's disease |
| 06/15/2006 | US20060128784 Bis-heteroaryl alkanes as therapeutic agents |
| 06/15/2006 | US20060128783 Tyrosine kinase inhibitors |
| 06/15/2006 | US20060128780 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 06/15/2006 | US20060128778 Amino acid composition for improving central functions |
| 06/15/2006 | US20060128776 Opioid receptor active compounds |
| 06/15/2006 | US20060128772 2-(2-methoxyphenyl)-3-(2-methoxy-phenyl)-5-phenylamino-(1,2,4)-thiadiazol-2 -ium; metabolic, nervous system and dermatological disorders, antidiabetic; obesity, impaired oral glucose tolerance, type II diabetes and Syndrome X, acne, dry skin and seborrheic dermatitis |
| 06/15/2006 | US20060128757 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 06/15/2006 | US20060128755 3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']-bipyridinyl-4-carboxylic acid (4-isopropylphenyl)amide; antiinflammatory and analgesic |
| 06/15/2006 | US20060128753 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments |
| 06/15/2006 | US20060128752 Chemical compounds |
| 06/15/2006 | US20060128749 Compounds |
| 06/15/2006 | US20060128746 Methods, kits and compositions for using pyrrole derivatives |
| 06/15/2006 | US20060128745 Chemical compounds |
| 06/15/2006 | US20060128734 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 06/15/2006 | US20060128731 Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine |
| 06/15/2006 | US20060128721 Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives |
| 06/15/2006 | US20060128705 Method of treating chronic fatigue syndrome |
| 06/15/2006 | US20060128701 N-{4-[ethyl-(2-hydroxy-ethyl)-amino]-phenyl}-2-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1- yl)-piperidin-1-yl]-acetamide; Eating disorders; CNS disorders; antidiabetic agents; psychological disorders; antiepileptic, antiinflammatory agents, autoimmune diseases; neuropeptide Y5 (NPY5) receptor antagonists |
| 06/15/2006 | US20060128700 e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia |
| 06/15/2006 | US20060128695 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 06/15/2006 | US20060128688 Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
| 06/15/2006 | US20060128659 Sulfotransferase inhibitors |
| 06/15/2006 | US20060128644 Use of mob-5 in pain |
| 06/15/2006 | US20060128643 Compositions containing a combination of a creatine compound and a second agent |
| 06/15/2006 | US20060128639 Regulators of the hedgehog pathway, compositions and uses related thereto |